Artesunate and cisplatin synergistically inhibit HNSCC cell progress and promote apoptosis.
PMID:
Oncol Rep. 2023 Aug ;50(2). Epub 2023 Jun 23. PMID: 37350399
Summary Title:
Artesunate and cisplatin synergistically inhibit HNSCC cell progress and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb ranges.
Summary:
Within the therapy of head and neck most cancers, cisplatin is usually used as a therapeutic agent; nonetheless, its efficacy is restricted and it might trigger renal dysfunction as an antagonistic impact. For that reason, using cisplatin is restricted in aged sufferers with diminished renal perform. Not too long ago, artemisinin, which was developed as an antimalarial drug, was discovered to have antitumor results and is efficient together with different anticancer medicine. Within the current research, the antitumor results of artemisinin and its derivatives in addition to their mixture with cisplatin and iron on head and neck squamous cell carcinoma cell traces, had been investigated. Cell viability was decided by a cell viability assay, the cell cycle was analyzed by stream cytometry, cell dying was assessed with annexin V and propidium iodide staining, and western blotting was used to research retinoblastoma protein (Rb), phosphorylated (p‑)Rb, and different cell cycle‑related molecules. A complete of 4 artemisinin compounds had been examined and it was discovered that artesunate and dihydroartemisinin had a big inhibitory impact on progress. It was additionally recognized that the mixture of artesunate, cisplatin, and iron inhibited cell proliferation and precipitated S/G2‑M cell cycle arrest. As well as, western blotting of Rb, a molecule concerned within the cell cycle, confirmed that artesunate induced the lack of not solely Rb but in addition p‑Rb. These outcomes urged that artesunate is a helpful drug together with cisplatin.
